Loading…
Trial eligibility change
| eligibility_criteria | Inclusion Criteria: * Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease * Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label * Participant must be an adult male or female, 18-64 years of age * Time since beginning of motor fluctuations ≤ 3 years * The Hoehn and Yahr (H\&Y) stage \< 3 in the on-medication condition * Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study Exclusion Criteria: * Previous Exposure to any device-aided therapy (DAT). * Any condition included in the contraindications section of the approved local LDp/CDp label. * Participants with Mini mental state examination (MMSE) score \< 24 | → | Inclusion Criteria: * Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease * Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label * Participant must be an adult male or female, 18-67 years of age * Time since beginning of motor fluctuations \<= 5 years * The Hoehn and Yahr (H\&Y) stage \<= 3 * Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study Exclusion Criteria: * Previous Exposure to any device-aided therapy (DAT). * Any condition included in the contraindications section of the approved local LDp/CDp label. * Participants with Mini mental state examination (MMSE) score \< 24 |
Not scored.No materiality record exists yet for this event.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.